<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112797</url>
  </required_header>
  <id_info>
    <org_study_id>ROX-ALE-2018-02</org_study_id>
    <nct_id>NCT04112797</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Treatment With A&quot;LLERGOVAC® HIMENÓPTEROS&quot; in Patients Sensitized to This Venom</brief_title>
  <acronym>HIPNOS</acronym>
  <official_title>Prospective Observational Study to Evaluate the Safety of Treatment With A&quot;LLERGOVAC® HIMENÓPTEROS&quot; in Patients Sensitized to This Venom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxall Medicina España S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxall Medicina España S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a safety and tolerability study of Allergovac Himenopteros in patients sensitized to&#xD;
      Apis mellifera, Polistes Dominula or Vespula spp. To get this aim all adverse reactions will&#xD;
      be recorded through the study. In addition, it will be evaluated the treatment efficacy with&#xD;
      the re-sting after a year of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by WAO classification</measure>
    <time_frame>During 1 year</time_frame>
    <description>All adverse events ocurred during the study Will be collected and clasified following the WAO recommendations. The percentages Will be exposed by number of patients and by dose administrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of vaccine evaluating re-sting test</measure>
    <time_frame>Result of the re-sting test</time_frame>
    <description>Grade of treatment protection after controlled sting</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergy to Himenoptera Venom</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac himenoptera</intervention_name>
    <description>Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People with allergy to himenoptera venom.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients over 14 years of age with allergy to bee venom, Polistes or Vespula. To&#xD;
             meet this criteria, patients must present a systemic reaction with the bite of one of&#xD;
             these insects, plus specific IgE detection in the skin test and / or IgE against the&#xD;
             himenoptera venom.&#xD;
&#xD;
             2. Prescription treatment with Hymenoptera venom must be indicated and patients are&#xD;
             susceptible to receive Allergovac® Hymenoptera, according to usual clinical practice.&#xD;
&#xD;
             3. Patients who have given their written consent. In the case of minors, the assent&#xD;
             will always be signed by the parent / legal guardian, in addition to the minor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received treatment with Allergovac® Hymenoptera prior to inclusion&#xD;
             in the study.&#xD;
&#xD;
          2. Patients under treatment with immunotherapy against aeroallergens.&#xD;
&#xD;
          3. Patients who have received previous treatment with immunotherapy, with any of the&#xD;
             venoms that they are going to receive, in the 5 years prior to the inclusion in the&#xD;
             study.&#xD;
&#xD;
          4. Patients who under investigator opinion may present difficulties that prevent the&#xD;
             comprehension of what was written in the information sheet for the patient, the&#xD;
             informed consent or the completion of self-administered questionnaires.&#xD;
&#xD;
          5. Patients who are participating in another clinical trial or observational study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>María Cruz Gómez, MP</last_name>
    <phone>+34 944438000</phone>
    <email>maricruz.gomez@roxall.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leire Begoña</last_name>
    <phone>+34 944438000</phone>
    <email>leire.begona@roxall.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Vega Baja Orihuela</name>
      <address>
        <city>Orihuela</city>
        <state>Alicante</state>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Ferrer</last_name>
      <email>angelyferrer@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Mexoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36313</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Arenas, MP</last_name>
      <email>luisarenas.alergia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>lluis Marqués, MP</last_name>
      <email>lmarques@gss.scs.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaspar Dalmau, MP</last_name>
      <email>gdalmau.hj23.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Hernández, MP</last_name>
      <email>hernandez_dol@gva.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

